How should hepatitis e virus infection be defined in organ-transplant recipients?

American Journal of Transplantation

Volumn 13, Issue 7, 2013, Pages 1935-1936

  Kamar, N ^a,b,c   Rostaing, L ^a,b,c   Legrand Abravanel, F ^b,c   Izopet, J ^b,c  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

FOLLOW UP; HEPATITIS E; HOSPITAL POLICY; HUMAN; LETTER; LIVER CIRRHOSIS; LIVER FIBROSIS; ORGAN TRANSPLANTATION; OUTPATIENT CARE; PRIORITY JOURNAL; RNA ANALYSIS; SOLID ORGAN TRANSPLANTATION;

CHRONIC DISEASE; FEMALE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RNA, VIRAL;

EID: 84879551514     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12253     Document Type: Letter

References (5)

1. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358 (8): 811-817.
2. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012; 379: 2477-2488.
3. Kamar N, Abravanel F, Selves J, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 2010; 89 (3): 353-360.
4. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication in patients with chronic hepatitis E virus infection. Gastroenterology 2010; 139 (5): 1612-1618.
5. Wedemeyer H, Pischke S, Manns MP., Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 2012; 142 (6): 1388-1397; e1381.